Head-to-head evidence
dupilumab vs stapokibart
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atopic Dermatitis
Shared mechanism: IL-4R-alpha · full Atopic Dermatitis pipeline
dupilumab · Dupixent
Marketed by Regeneron Pharmaceuticals and partners
NCT01949311 · Phase 3 · completed
This was an explicitly described open-label extension enrolling participants from prior dupilumab atopic dermatitis trials, including the SOLO 1 and SOLO 2 programs, with 2,677 participants receiving dupilumab in a single group. The primary outcomes were safety events rather than a comparative efficacy endpoint, and there was no randomization, blinding, or control arm; therefore, the findings provide limited evidence despite the large enrollment.
Next expected readout: October 2026 · NCT02612454 (registry estimate)
stapokibart
Developed by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. and partners
NCT05265923 · Phase 3 · completed
In this randomized, double-blind, placebo-controlled Phase 3 trial in 500 adults with moderate-to-severe atopic dermatitis, significantly more patients receiving stapokibart achieved at least a 75% reduction in eczema severity at 16 weeks than those on placebo (66.9% vs 25.8%).
Next expected readout: February 2027 · NCT07106372 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: dupilumab's landscape · stapokibart's landscape